23.80
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BAX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$24.18
Offen:
$24.65
24-Stunden-Volumen:
5.45M
Relative Volume:
0.85
Marktkapitalisierung:
$12.30B
Einnahmen:
$11.32B
Nettoeinkommen (Verlust:
$-981.00M
KGV:
-12.19
EPS:
-1.9532
Netto-Cashflow:
$714.00M
1W Leistung:
-7.86%
1M Leistung:
-13.80%
6M Leistung:
+31.86%
1J Leistung:
-2.82%
Baxter International Inc Stock (BAX) Company Profile
Firmenname
Baxter International Inc
Sektor
Telefon
(224) 948-2000
Adresse
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX vs ISRG, BDX, ALC, RMD, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
BAX
Baxter International Inc
|
23.80 | 12.30B | 11.32B | -981.00M | 714.00M | -1.9532 |
|
ISRG
Intuitive Surgical Inc
|
369.15 | 130.41B | 11.03B | 3.16B | 3.22B | 8.7251 |
|
BDX
Becton Dickinson Co
|
177.85 | 48.44B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
ALC
Alcon Inc
|
66.03 | 31.92B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
RMD
Resmed Inc
|
218.27 | 31.49B | 5.54B | 1.52B | 1.74B | 10.37 |
|
MDLN
Medline Inc
|
32.53 | 28.54B | 29.14B | 1.07B | 1.05B | 1.1956 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Herabstufung | Argus | Buy → Hold |
| 2025-08-04 | Herabstufung | Stifel | Buy → Hold |
| 2025-08-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-26 | Fortgesetzt | Goldman | Buy |
| 2025-02-24 | Hochstufung | Argus | Hold → Buy |
| 2025-02-20 | Fortgesetzt | Barclays | Overweight |
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-06-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-18 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-18 | Bestätigt | Raymond James | Outperform |
| 2022-02-18 | Bestätigt | Stifel | Buy |
| 2022-02-18 | Bestätigt | UBS | Neutral |
| 2022-02-18 | Bestätigt | Wells Fargo | Overweight |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
| 2022-01-07 | Fortgesetzt | Citigroup | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-09-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Herabstufung | UBS | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-09-04 | Herabstufung | Argus | Buy → Hold |
| 2020-06-24 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-19 | Hochstufung | Stifel | Hold → Buy |
| 2020-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-02 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Hochstufung | Argus | Hold → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-05-17 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-06 | Bestätigt | Citigroup | Neutral |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
Alle ansehen
Baxter International Inc Aktie (BAX) Neueste Nachrichten
Baxter International Inc Share PriceBAX, RNS News, Articles, Quotes, & Charts (NYSE:BAX) - Proactive financial news
Securities Lawsuit Alert: Baxter International, Inc. (BAX) – Contact Levi & Korsinsky Before December 15, 2025 - ACCESS Newswire
Baxter International Inc. stock underperforms Friday when compared to competitors - MarketWatch
Baxter International stock heads into the open after a modest gain - ad-hoc-news.de
Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider - GlobeNewswire Inc.
Baxter International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Transcript : Baxter International Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 12 - marketscreener.com
Baxter at Wells Fargo conference: growth improves as turnaround continues By Investing.com - Investing.com UK
A Look at Baxter International Inc (BAX) After 3.8% Decline -- G - GuruFocus
Baxter International stock trades sideways as technical signals flag limited near-term upside - ad-hoc-news.de
Baxter International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Baxter International stock holds steady as investors await next earnings signal - ad-hoc-news.de
BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure - Yahoo Finance
Human Albumin Market Report Analyzes Growth Factors, Challenges, and Market Dynamics - openPR.com
Don't Ignore The Insider Selling In Abeona Therapeutics - simplywall.st
Baxter International Inc. (BAX) Stock Analysis: Exploring Potential Upside and Analyst Ratings - DirectorsTalk Interviews
Nagaraj Bhat Appointed Vice President/GM, Global Capability Center (GCC) Site Leader at DePuy Synthes - hrtoday.in
Baxter International stock holds steady as investors focus on recent restructuring and earnings prof - ad-hoc-news.de
ETFs Investing in Baxter International Inc. Stocks - TradingView
Before Mark Walter’s companies faced inquiries, he kept a low profile and built loyalty - Los Angeles Times
Two IV Saline Recalls Within Days Cite Iron Oxide and Fiberglass Particles Found Inside Sealed Hospital Bags - Medical Daily
IV bags recalled in MD over potential fiberglass contamination - Maryland Daily Record
Baxter International Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Baxter International stock holds steady as investors digest latest quarterly figures - ad-hoc-news.de
Jerry Flansburg Obituary (2026)International Falls, MNRainy Lake Gazette - Legacy obituary
Baxter International CEO Andrew P. Hider Surrenders Shares for Tax Withholding on September 2, 2026 - Kalkine Media
Baxter (NYSE: BAX) exec ends with 29,164 shares after tax move - Stock Titan
Recalls issued for possible fiberglass particles in IV solutions made at WNC facility: FDA - WLOS
Baxter International stock gains after strong Q2 figures - ad-hoc-news.de
Taiwan's Best Companies to Work for in Asia Transformed a Talent Crisis into a Strategic Advantage - PR Newswire
Baxter International stock holds gains as recalls and earnings shape sentiment - AD HOC NEWS
Baxter International stock could double, Tom Hayes says - finance.yahoo.com
FDA recalls saline bags in 14 states over possible fiberglass contamination - thecooldown.com
Baxter International stock steadies as recall news meets mixed analyst view - AD HOC NEWS
Baxter International Inc. (BAX) Stock Analysis: Exploring a 9.94% Potential Upside Amidst Healthcare Sector Dynamics - DirectorsTalk Interviews
Baxter: This Turnaround Stock Is Up and Still 38% Undervalued - Morningstar
2 drugs recalled over potential fiberglass, steel presence - WGN-TV
Saline bags recalled in 14 states due to potential fiberglass contamination - kare11.com
Fiberglass in IV saline? Texas among states included in recall - MySA
Baxter International Inc. (BAX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Saline used in IV injections recalled nationwide due to fiberglass - FOX 8 News
Baxter International Inc. stock outperforms competitors despite losses on the day - MarketWatch
FDA announces drug recalls over potential presence of fiberglass, steel - NewsNation
Licensable picture: Baxter International CEO and President Robert Parkinson Jr. looks over at the families of the victims of Heparin reactions testifying during a House Energy and Commerce subcommittee hearing on Heparin imports from China on Capitol Hill - reutersconnect.com
Baxter Recalls an IV Nutrition Solution After Stainless Steel Particles Turned Up Inside the Sterile Bag - Medical Daily
Baxter Issues Voluntary Nationwide Recall for One Lot of Anticoagulant Sodium Citrate Solution Due to Potential Presence of Particulate Matter - USA Today
Baxter International Inc. (BAX) Stock Analysis: Navigating Challenges with Potential 9.06% Upside - DirectorsTalk Interviews
Baxter International stock holds steady as new CFO joins and analyst estimates shift - Ad-hoc-news.de
Zacks Research Issues Negative Estimate for BAX Earnings - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Takes Position in Baxter International Inc. $BAX - MarketBeat
Baxter International (BAX) Taps John Rogers As Chief Financial Officer - Sahm
Finanzdaten der Baxter International Inc-Aktie (BAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):